Abstract:Background: Amyloidoses are characterized by the extracellular deposition of insoluble fibrillar proteinaceous aggregates highly organized into cross-β structure and referred to as amyloid fibrils. Nowadays, the diagnosis of these diseases remains tedious and involves multiple examinations while an early and accurate protein typing is crucial for the patients' treatment. Routinely used neuroimaging techniques such as magnetic resonance imaging (MRI) and positron emission tomography (PET) using Pittsburgh compound B, [(11)C]PIB, provide structural information and allow to assess the amyloid burden, respectively, but cannot discriminate between different amyloid deposits. Therefore, the availability of efficient multimodal imaging nanoparticles targeting specific amyloid fibrils would provide a minimally-invasive imaging tool useful for amyloidoses typing and early diagnosis. In the present study, we have functionalized gadolinium-based MRI nanoparticles (AGuIX) with peptides highly specific for Aβ amyloid fibrils, LPFFD and KLVFF. The capacity of such nanoparticles grafted with peptide to discriminate among different amyloid proteins, was tested with Aβ(1-42) fibrils and with mutated-(V30M) transthyretin (TTR) fibrils. Results: The results of surface plasmon resonance studies showed that both functionalized nanoparticles interact with Aβ(1-42) fibrils with equilibrium dissociation constant (Kd) values of 403 and 350 µM respectively, whilst they did not interact with V30M-TTR fibrils. Similar experiments, performed with PIB, displayed an interaction both with Aβ(1-42) fibrils and V30M-TTR fibrils, with Kd values of 6 and 10 µM respectively, confirming this agent as a general amyloid fibril marker. Thereafter, the ability of functionalized nanoparticle to target and bind selectively Aβ aggregates was further investigated by immunohistochemistry on AD like-neuropathology brain tissue. Pictures clearly indicated that KLVFF-grafted or LPFFD-grafted to AGuIX nanoparticle recognized and bound the Aβ amyloid plaque localized in the mouse hippocampus. Conclusion: These results constitute a first step for considering these functionalized nanoparticles as a valuable multimodal imaging tool to selectively discriminate and diagnose amyloidoses.

M13 phage grafted with peptide motifs as a tool to detect amyloid-β oligomers in brain tissue

Gd-nanoparticles functionalization with specific peptides for ß-amyloid plaques targeting

Phage display affords peptides that modulate beta-amyloid aggregation.

A Novel Viscosity Sensitive Hemicyanine Fluorescent Dye for Real-Time Imaging of Amyloid-Β Aggregation

Phage display and kinetic selection of antibodies that specifically inhibit amyloid self-replication

Dual-functional Nanoparticles Targeting Amyloid Plaques in the Brains of Alzheimer's Disease Mice

An AIE-Active NIR Fluorescent Probe with Good Water Solubility for the Detection of Aβ1–42 Aggregates in Alzheimer’s Disease

Detection of Aβ Plaques by a Novel Specific MRI Probe Precursor CR‐BSA‐(Gd‐DTPA)n in APP/PS1 Transgenic Mice

Nanozyme sensor array based on manganese dioxide for the distinction between multiple amyloid β peptides and their dynamic aggregation process

Advances in targeted tracking and detection of soluble amyloid-β aggregates as a biomarker of Alzheimer's disease

Development of SERS Active Nanoprobe for Selective Adsorption and Detection of Alzheimer's Disease Biomarkers Based on Molecular Docking

Exploring the Abeta Plaque Microenvironment in Alzheimer's Disease Mice by Multimodal Lipid-Protein-Histology Imaging on a Benchtop Mass Spectrometer

A Β-Sheet-targeted Theranostic Agent for Diagnosing and Preventing Aggregation of Pathogenic Peptides in Alzheimer’s Disease

Phage display derived peptides for Alzheimer's disease therapy and diagnosis

Visual and Fluorescent Assays for Selective Detection of Beta-Amyloid Oligomers Based on the Inner Filter Effect of Gold Nanoparticles on the Fluorescence of CdTe Quantum Dots.

Quantitative detection of amyloid-β peptides by mass spectrometry: state of the art and clinical applications

Regenerable and Simultaneous Surface Plasmon Resonance Detection of Aβ(1−40) and Aβ(1−42) Peptides in Cerebrospinal Fluids with Signal Amplification by Streptavidin Conjugated to an N-Terminus-Specific Antibody

Advances in development of fluorescent probes for detecting amyloid-β aggregates

An AIE-active Theranostic Probe for Light-Up Detection of Aβ Aggregates and Protection of Neuronal Cells.

D-A-D Fluorogenic Probe for the Rapid Imaging of Amyloid Β Plaques in Vivo

Strategies for Measuring Concentrations and Forms of Amyloid-Β Peptides